While the results may have missed some analysts’ expectations, they have overall remained quite positive on the stock, as they expect the group’s China business to see growth. During the first half period, the China business saw a marginal revenue increment from RMB162.9 million ($30.5 million) to RMB163.6 million. Cost-saving measures that were put in place earlier have proven effective in reducing initial losses.
Raffles Medical Group (RMG) on July 28 announced its 1HFY2025 ended June 30 results, which saw earnings gain 4.8% y-o-y to $32.1 million from $30.6 million previously, supported by stable operational performance across core segments.
Revenue for the period saw a 3.5% growth to $378.4 million from $365.7 million last year, with its healthcare services, hospital services and insurance services divisions seeing growth.
